Memphis Pharmaceuticals results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit90.44 millionEGP · +22.1% vs the same period a year earlier
Total assets786 millionEGP · +40.2% vs the same period a year earlier
Shareholders' equity105 millionEGP · +186.4% vs the same period a year earlier
Operating cash flow57.94 millionEGP · +58.9% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q4 2023 was about 90.44 million EGP, up +22.1% from 74.09 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 786 million EGP, and shareholders' equity about 105 million EGP.
- Operating cash flow for Q4 2023 was positive at 57.94 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit90.44 million74.09 million+22.1%
Gross profit217 million157 million+38.2%
Total assets786 million560 million+40.2%
Total liabilities681 million524 million+30.0%
Shareholders' equity105 million36.64 million+186.4%
Total liabilities and equity786 million560 million+40.2%
Operating cash flow57.94 million36.47 million+58.9%
Investing cash flow-582 thousand-3.38 million+82.8%
Financing cash flow-294 million——
Net change in cash59.7 million31.23 million+91.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy